Platform for Drug Development and Innovation Support (PADIM)

The Platform for Drug Development and Innovation (PADIM) focuses on the development and evaluation of new therapeutic agents targeting specific molecular sites, employing a rational drug design and metabolomics-based approach.

To achieve these objectives, PADIM develops experimental strategies that enable the identification and characterization of pharmacological targets, as well as the search for new therapeutic agents against them.

Additionally, the PADIM team has extensive expertise in the design of protein constructs, their purification, and their biochemical, biophysical, and structural characterization. They are also highly experienced in the identification of new targets and biomarkers with clinical utility in the diagnosis and treatment of cancer. The research team members come from the pharmaceutical industry and maintain close collaborations with various companies in the field of fragment-based drug discovery-small molecular weight compounds with modest affinities for pharmacological targets.

PADIM collaborates with different research groups and consortia, both nationally and internationally, on projects aimed at identifying new biomarkers and therapeutic targets in cancer, with the ultimate goal of developing novel molecules to modulate target activity. Furthermore, PADIM engages in joint projects with various companies focusing on the identification and evaluation of fragments-small molecular weight compounds that exhibit modest affinities for pharmacological targets.

At the national level, several scientific and technological platforms provide isolated services in the field of drug discovery, but none offer an integrated approach. In this context, PADIM stands out as the only technological platform that provides a comprehensive and unified suite of innovative experimental approaches in drug discovery. This unique feature represents a significant competitive advantage over other available scientific and technological services, as it allows for a more optimized drug development process by enabling the sequential evaluation and analysis of various pharmacological properties.

These services are further complemented by PADIM's expertise in identifying pharmacological and clinical biomarkers for diagnostic and/or prognostic applications in different diseases, patient stratification and monitoring, drug mechanism of action characterization, and safety/efficacy profile evaluation.

Overall, PADIM offers collaboration and specialized services in the identification of novel biomarkers and therapeutic targets, as well as in the development of new drugs.